Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Sees Large Growth in Short Interest

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 8,100 shares, an increase of 406.3% from the December 31st total of 1,600 shares. Based on an average trading volume of 356,600 shares, the days-to-cover ratio is currently 0.0 days.

Enzon Pharmaceuticals Price Performance

Enzon Pharmaceuticals stock traded down $0.00 during midday trading on Tuesday, reaching $0.13. The company’s stock had a trading volume of 3,840 shares, compared to its average volume of 91,967. The stock’s 50-day simple moving average is $0.13 and its 200-day simple moving average is $0.13. The stock has a market capitalization of $9.51 million, a P/E ratio of 12.83 and a beta of 0.27. Enzon Pharmaceuticals has a 52-week low of $0.06 and a 52-week high of $0.24.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.